Obesity {#S1}
=======

Obesity is defined as an excessive accumulation of fat associated with adverse health consequences and results from the complex interaction of socioeconomic, genetic, epigenetic, and lifestyle factors ([@B146]). Obesity prevalence has now reached epidemic proportions, affecting up to 1.9 billion adults worldwide, including 650 million patients who are clinically obese. The body mass index (BMI) is used to stratify adult patients as underweight (\<18.5), normal weight (18.5--24.9), overweight (25--29.9), or obese (\>30). The severity of obesity is further classified as class: I (30--34.9), II (35--39.9), or III (\>40) ([@B146]).

In terms of mortality, it has been projected that obesity and obesity-associated chronic diseases will account for almost three-quarters of all deaths worldwide by 2020 ([@B145]). Thus, obesity is highly comorbid and constitutes a key risk factor for developing insulin resistance and type II diabetes, cardiovascular diseases, cancer, and dementia ([@B71]). In addition to these, obesity is now considered an important pain facilitator, as BMI and pain perception are strongly correlated ([Table 1](#T1){ref-type="table"}). For example, 40% of obese suffer from chronic pain, and the pain they report is more severe, often intractable, seeking more medical attention and consuming more painkillers ([@B130]). Inversely, patients suffering from chronic pain are also more likely to become obese ([@B122]). Being highly prone to develop osteoarthritis (OA), they chiefly report musculoskeletal pain ([@B73]). Finally, obesity-induced pain varies with the patients' sex, diet, and body fat distribution.

###### 

Pain sensitivity correlate with obesity status.

  Patient sample               Pain site         Obesity prevalence among patients (%)   References
  ---------------------------- ----------------- --------------------------------------- ------------
  1 million adults             Diverse           44                                      [@B122]
  5,724 elderly                Knee              58                                      [@B3]
  721 adults                   Headache          30                                      [@B131]
  300 children and teenagers   Musculoskeletal   56                                      [@B129]
  182 adults                   Diverse           40                                      [@B32]
  100 adult women              Fibromyalgia      45                                      [@B97]

While significant advances were made in the understanding of the molecular mechanisms driving persistent pain, this knowledge has yet to translate into effective therapies. Thus, the management of chronic pain still constitutes a significant unmet clinical need ([@B155]). The following section will explore the molecular mechanism and the relative contribution of (i) mechanical stress; (ii) chronic low-grade inflammation; and (iii) neuro-immunity to obesity-induced pain; and whether targeting such mechanism may constitute a therapeutic strategy to alleviate sensory hypersensitivity.

Organization of the Nervous System and Pain Sensation {#S2}
=====================================================

The nervous system is designed to quickly detect stimuli and direct avoidance behavior ([@B15]). In the periphery, autonomic neurons monitor and regulate organ functions (involuntary) while the somatic (voluntary) system provides sensitivity and motor control. In addition to these, nociceptors are a peripheral population of unmyelinated (C-fibers) or thinly myelinated (Aδ fibers) neurons specialized in sensing potentially damaging stimuli (pressure, temperature, chemical). These signals are transduced in electrical impulses, which are integrated centrally. In turn, effector signals are produced and transmitted to motor neurons activating muscle contraction ([@B1]) and occasionally tuning immune responses.

Upon activating nociceptor, the host generally experienced pain, which is defined as an unpleasant sensory and emotional experience ([@B61]). Pain is either acute, serving a protective physiological response to a harmful stimulus, or chronic, when physically debilitating and lasting over 3 months ([@B61]). Pain can also be stratified as (i) nociceptive, associated with the detection of potentially harmful tissue-damaging stimuli ([@B150]); (ii) neuropathic, triggered by an injury/disease to the somatosensory nervous system ([@B33]); (iii) dysfunctional, when associated to a disease state of the nociceptive nervous system (i.e., fibromyalgia) ([@B94]); or (iv) inflammatory, associated with tissue damage and active inflammation ([@B106]).

Nociceptors detect not just features typically thought of as causing a painful sensation, such as chemical and noxious temperature, but uncharacteristic signals ranging from cytokines, fungi, microbes, and immunoglobulins ([@B110]). A revised portrait of neuron danger sensing include (i) ion channel transducers \[transient receptor potential (TRP), Piezo\]; (ii) receptor for sensitizing mediators \[Mas-related G protein--coupled receptor (Mrgpr), prostaglandins (PG), protons (H), bradykinin (BK), etc.\]; (iii) threat detectors including receptors for immunocyte-produced mediators (interleukins, chemokines, and immunoglobulins); and (iv) damage-associated molecular pattern (DAMP) detector ([@B36]). Damage-associated molecular patterns, which include protease-activated receptors (PARs), toll-like receptors (TLRs), and pattern recognition receptors (PRRs), are families of specialized receptors for microbial proteins, and play an essential role in preserving mucosal homeostasis. Overall, nociceptors' transcriptional data show the enormous variety of threat detection competences of nociceptor neurons, including immunocyte-produced cues ([@B147]; [@B112]; [@B123]; [@B101]; [@B48]).

Inflammatory pain is characterized by the influx of immunocyte-producing cytokines, chemokines, and growth factors. These mediators typically bind to G protein-coupled receptors (GPCRs) and/or tyrosine kinase receptors expressed by nociceptor terminals and lead to intracellular kinases activation. Subsequently, these kinases decrease the activation threshold of ion channel transducer \[i.e., transient receptor potential vanilloid-1 (TRPV1); transient receptor potential cation channel, subfamily A, member 1 (TRPA1)\] and voltage-gated sodium channels (Na~V~) (i.e., Na~V~1.7, Na~V~1.8, and Na~V~1.9) ([@B25]; [@B70]; [@B96]; [@B2]; [@B16]) or increased their membrane expression ([@B69]). Consequently, these effects sensitized nociceptors, which results in hypersensitivity to non-noxious stimuli, a situation termed allodynia ([@B151]; [@B150]). Besides, the nerve terminal "sensitized" state intensifies the response to painful trigger (termed hyperalgesia). Such hypersensitivity focuses the host on the injury site and leads to alternative behavioral (i.e., gait change). These effects are typically limited to the inflammatory sites, while systemic hypersensitivities result from central sensitization ([@B124]; [@B110]); see detailed review by [@B151] and [@B150].

Known nociceptor sensitizer includes prostaglandin E~2~ (PGE~2~) produced by cyclooxygenase 2 (COX2) and nerve growth factor (NGF). Nociceptors express receptors for and were found to be sensitized by interleukin (IL)-1β ([@B19]) or Chemokine (C-C motif) ligand 3 (CCL3) ([@B156]) in the context of pain, IL-5 in asthma ([@B123]), IL-4 and thymic stromal lymphopoietin (TSLP) in atopic dermatitis ([@B101]), IL-31 during itch ([@B26]), IL-33 after contact with poison ivy ([@B84]), and IL-23 in the context of psoriasis ([@B112]).

Inflammation {#S3}
============

Characterized by its pain, heat, redness, and edema ([@B79]), inflammation suggests an immune-mediated phenomenon, but each of these characteristics can also stem from neuronal activation. Typically, noxious stimuli-induced action potential travels to the brain to initiate sensation ([@B128]; [@B7]). When they reach the sensory neuron branch points, these electrical signals are also transmitted antidromically, back to the peripheral terminals, to initiate neurogenic inflammation via the local release of neuropeptides ([@B111]; [@B29]). Subsequently, these peptides act on the endothelium to generate redness and heat (secondary to vasodilation) and edema (extravazation due to enhanced capillary permeability) ([@B46]; [@B143]).

Immunity in Host Defense {#S4}
========================

Innate immunity is the primary barrier against microbes ([@B64]), while adaptive immunity generated long-term antigen memory ([@B83]). Antigen-presenting cells integrate danger signals and communicate information to T helper cells driving either of type 1 (against intracellular microbes), type 2 (against parasites), or type 17 (against extracellular pathogens) responses ([@B63]). Other immunocytes include mast cells (type 2 effector cells) ([@B90]; [@B10]), neutrophils (type 1 and 17 effector cells) ([@B88]), and macrophages ([@B60]). Macrophages have an incredible plasticity ranging from M1 macrophages (IL-1β^+^, TNF-α^+^), which are involved in cell elimination, to M2 macrophages (IL-10^+^, TGF-β^+^), partaking in tissue restoration. Besides, innate lymphoid cells (ILCs) are tissue-resident T~H~ cytokine-expressing cells (Lin^--^: TCRβ^+^, CD3ε^+^, CD19^+^, TCRγδ^+^, Ly6G^+^, F4/80^+^) ([@B120]), and as CD4 T cells, they are divided into three groups. ILC1 are T~H~1-like cells and produce INF-γ; ILC2 are T~H~2-like cells, express GATA3 and RORα, and produce IL-4, IL-5, and IL-13, while ILC3 are T~H~17-like, express RORγt, and secrete IL-17 and IL-22 ([@B6]). In the function of the cytokines they express, they guide response against pathogens, parasite, and fungi ([@B6]) and are also involved in autoimmune and inflammatory diseases ([@B51]; [@B137]).

Mechanical Stress {#S5}
=================

Sustained overloading on the musculoskeletal structure of the lower back, hip, and knee joints prompts the development of OA in obese patients ([@B73]). Obesity-related OA is multifactorial and involves direct joint damage as well as genetic, biological, and metabolic factors ([@B38]). For instance, increased mechanical load changes the chondrocyte mechanotransducer signaling ([@B58]), promotes cytokine secretion (IL-1β, IL-6, and TNF-α) and matrix metalloproteinases release, and contributes to establishing a pro-oxidative microenvironment ([@B121]). These prompts the degradation of type II collagen, joint extracellular matrix, and hyaluronic acid fragmentation. These factors caused (i) imbalance between deterioration and repair of the cartilage; (ii) chondrocyte apoptosis; (iii) reduced synoviocyte fluid viscosity; and (iv) increased joint friction, all of which changed the patients' posture and gait, reducing their mobility and increasing pain scores ([@B68]).

While OA affects 16% of adults, it is present in 23% of overweight and 31% of obese patients ([@B138]). As such, obese patients are 35% and 11% more at risk of developing knee and hip OA, respectively ([Table 2](#T2){ref-type="table"}; [@B66]). Knee radiograph showed smaller width of the medial and lateral joint space in obese patients ([@B30]), resulting in a 35% greater risk to undergo knee arthroplasty ([@B21]).

###### 

Obesity-mediated osteoarthritis (odds ratio).

  Site       Obesity-related OR   References
  ---------- -------------------- ------------
  Knee       1.6                  [@B43]
  Hip        2.0                  [@B82]
  Hands      1.3                  [@B54]
  Low back   4.3                  [@B85]

These effects may be partly explained by the production of adipose tissue (AT)-secreted adipokines (leptin and adiponectin) ([@B39]). These adipokines, whose circulating and cartilage levels correlate with BMI, activate their cognate receptors on the surface of chondrocytes, increasing the production of matrix metalloproteinases, nitric oxide (NO), and cytokines (IL-1β, IL-6, IL-8, TNF-α) ([@B45]). In turn, these mediators heighten synovial inflammation and pain hypersensitivity by driving fibroblast proliferation and immune cell infiltration ([@B50]).

Obesity, a Low-Grade Inflammation Disease {#S6}
=========================================

White adipose tissue (WAT) comprised pre-adipocytes, adipocytes, endothelial cells, and immunocytes and has a primary role in energy storage. Adipocytes originate from mesenchymal stem cells ([@B109]), and their production is mainly controlled by epigenetic regulators, growth factors, and CCAAT-enhancer-binding proteins (or C/EBPs) and peroxisome proliferator-activated receptor γ (PPARγ) transcriptional regulators ([@B152]). Increased mitochondrial metabolism and biogenesis results in reactive oxygen species production, which initiate adipocyte differentiation in a mammalian target of rapamycin complex 1 (mTORC1)-dependent manner ([@B132]). White adipose tissue content strikingly increases during obesity and, therefore, constitutes a predominant source of circulating hormones, peptides, cytokines, and adipokines ([@B59]).

It is increasingly recognized that immunological factors drive obesity induction, a phenomenon present in the WAT as well as pancreas, liver, and intestines ([@B103]; [@B67]; [@B148]). Thus, lean AT is mainly composed of M2 macrophages, ILC2s, eosinophils, regulatory T cells (Tregs), and T~H~2 cells, while the obese fat pad is dominated by neutrophils, ILC1, M1 macrophages, and cytotoxic T cells. Similarly, the fat stromal vascular fraction of lean mice is composed of anti-inflammatory immune cells such as M2 macrophages ([@B86]), Treg ([@B44]), and ILC2 ([@B93]). In contrast, M1 macrophages represent 10% and 40--50% of obese mice and patient stromal fractions, respectively ([@B102]; [@B20]). Such alternative and inflammatory composition support insulin resistance and maintain low-grade inflammation.

Adipocytes release the monocyte chemoattractant protein-1 (MCP-1), which attracts C-C chemokine receptor type 2 (CCR2)-expressing monocytes and favors their differentiation into M1 macrophages ([@B5]). Once in the WAT, macrophages form "crown-shaped structures" around dead adipocytes ([@B31]), producing TNF-α, IL-1β, and IL-6 ([@B86]). Therefore, M1 macrophages constitute one of the main source of cytokines in obese-WAT ([@B87]) and, through PPARγ production, stimulate adipogenesis ([@B115]). In addition, adipocytes tend to rupture due to their limited expansion capacity observed during obesity. The massive apoptosis of these cells drastically increased the levels of cytokines within the fat pad microenvironment and leads to the chemotaxis of M1 macrophages ([@B87]).

Along with macrophages, the numbers of circulating monocyte and neutrophil increased during obesity ([@B107]). Given that monocytes originate from hematopoietic stem cells (HSCs) and that obese patients have increased circulating HSCs progenitors, it was posited that HSCs might give rise to leukocyte influx ([@B17]). Thus, HSCs enhance macrophage generation, via the myeloid differentiation primary response 88 (MyD88), a protein known to serve as an intermediate between extracellular danger signals sensed by TLR and the activation of the transcription factor nuclear kappa β (NF-κB) ([@B117]). These macrophages then go on to accumulate within the dorsal root ganglion (DRG) of high-fat diet (HFD)-fed mice ([@B118]).

Diet-induced obesity CD4^+^ T lymphocytes were found to have biased T cell receptor (TCR) repertoires, suggesting an antigen-specific expansion. Glucose homeostasis typically becomes dysregulated in diet-induced obesity, when numbers of IFN-γ-secreting T~H~1 cells overwhelm the non-expending pools of T~H~2 (CD4^+^GATA-3^+^) and Tregs (CD4^+^CD25^+^Foxp3^+^). Through T~H~2 cell increases, CD4^+^ T cell transfer into HFD Rag1^--/--^ animals reversed weight increase and insulin resistance. Transient CD3 depletion also restores the T~H~1/Treg balance and reverses HFD-induced insulin resistance, suggesting an upstream role for CD4^+^ T cell in controlling obesity-associated metabolic abnormalities ([@B149]).

Adipose tissue macrophages (ATM) initiate WAT inflammation. However, recent data suggest that other tissue-resident innate immune cells, such as ILCs, also are major contributors ([@B154]). ILC2 number decreased in obese mice epididymis and human subcutaneous WAT ([@B22]). Being resident in lean AT, ILC2s maintain a T~H~2-like status of AT ([@B93]), in which ILC2-produced IL-5 and IL-13 promote the beiging of WAT ([@B93]; [@B22]; [@B56]). These effects are present in *Rag1* null mice and are, therefore, independent of tissue-resident M2 macrophages ([@B55]; [@B93]). Thus, IL-33-driven WAT biogenesis suggests another role for an ILC2-inducing cytokine in regulating obesity ([@B22]; [@B80]). In effect, IL-33 null mice gain more weight than their wild-type counterpart and have reduced frequency of ILC2s. This phenomenon is also present in IL-33 KO mice fed a normal diet ([@B22]). Exogenous IL-33 rescued WAT ILC2s number and M2 macrophage ([@B22]).

High-fat diet -exposed mice have enhanced IFN-γ levels ([@B144]). The depletion of natural killer (NK) cells decreased HFD-induced insulin resistance and M1 macrophage levels but stopped the onset of obesity. Inversely, the adoptive transfer of splenic NK cells into IFN-γ null animals restores HFD-mediated insulin resistance ([@B144]). Tissue-resident ILC1 may directly promote obesity-induced insulin resistance without the influence of natural killer T (NKT) or T cells ([@B104]). IL-12 activated ILC1 lead IFN-γ production and subsequent polarization of M1 macrophages ([@B104]). ILC1-derived IFN-γ balanced out the effect of IL-33 mediated ILC2 activation within visceral AT ([@B100]), providing an *in situ* negative regulators of ILC2 anti-obesity effects.

While untested, ILC3-derived IL-17 may drive obesity-related comorbidities ([@B72]). Thus, Rag1 and IL-17, a double knockout mice, failed to develop asthma exacerbation when fed with a HFD ([@B72]). ILC3-producing IL-22 promote liver metabolism and help stop insulin resistance ([@B142]). Accordingly, *IL-22R* null mice were highly susceptible to HFD-induced obesity and insulin resistance. In obese mice, exogenous IL-22 tones down diabetes-induced oxidative stress and islet β inflammation, rescuing insulin secretion and glucose sensitivity ([@B57]).

Overall, the influx and polarization of immunocytes by WAT-derived mediators enhance fat accumulation, speed up joint damages, and may directly sensitize nociceptor, as discussed in the next section. Blocking the inflammatory component of obesity may, therefore, constitute a potential therapeutic avenue to stop obesity progression and its comorbidities.

Innervation of the Wat {#S7}
======================

Under the control of a complex set of humoral and neural factors ([@B62]; [@B40]; [@B125], [@B126]; [@B42]), WAT-released mediators tuned the host energy status as well as the number and phenotype of immune, vascular, and structural cells ([@B105]). Along with blood-derived factors, adipocyte size, lipid mobilization, and paracrine secretion are controlled by sensory nerve terminals ([@B14]). Thus, fat pad sensory innervation is increased in obesity ([@B9]; [@B135]). In addition, evidences suggest a dual, yet segregated, sympathetic and parasympathetic innervation of WAT ([@B76]). We refer the reader's attention to the work of Bartness and colleagues for more information on WAT innervation ([@B13]). Overall, neurons control WAT production of cytokines and immune influx, making fat innervation a central component player in obesity-induced low-grade inflammation.

Autonomic Nervous System in Obesity {#S8}
===================================

Sympathetic neurons control catabolic functions ([@B91]) via neuropeptide Y (NPY) suppression of lipolysis and promotion of angiogenesis and heighten adipocyte differentiation ([@B77]). It is worth noting that adipocytes and macrophage-produced cytokines increase sympathetic flow, while excessive cytokine levels, such as during severe inflammation, have the opposite effect ([@B108]).

Parasympathetic vagal neurons that innervate the fat pad have anabolic functions helping tune insulin-mediated glucose and free fatty acid uptake and help promote lipid accumulation ([@B12]). Conversely, lipid accumulation further increases their anabolic functions ([@B12]). In doing so, norepinephrine controls triacylglycerol lipolysis, NO production, and tissue remodeling ([@B98]). Fat pad denervation decreased transcript expression of resistin and leptin, without impacting the levels of adiponectin. It, therefore, supports an anabolic role for WAT-parasympathetic neurons ([@B12]; [@B76]).

These data support the long appreciated contribution of parasympathetic neurons as an inhibitor of splenic macrophage-mediated inflammation ([@B133]; [@B4]). Thus, spleen innervating adrenergic activates acetylcholinergic T cells ([@B114]). By stimulating splenic macrophages' alpha-7 nicotinic receptor, acetylcholine stops their production of TNF-α ([@B141]).

Harnessing such inflammatory reflex using bioelectronic devices ([@B27]), non-invasive vagus neurons activate blunt inflammation in arthritic patients ([@B75]) and mice with experimental inflammatory bowel disease ([@B65]). As such, parasympathetic neuron activation constitutes an innovative approach to tone down systemic inflammation, obesity progression, and obesity-associated comorbidities, such as pain hypersensitivity.

Neuro-Immunity {#S9}
==============

The sensory nervous and immune systems work together to promote host defense and homeostasis ([@B128]) and interact through a common language of receptors, cytokines, neuropeptides, and enzymes ([@B35]). While this crosstalk is adaptive, protecting the host from threat, it drives disease pathophysiology ([@B28]; [@B147]; [@B123], [@B128]; [@B48]). In addition to prompting withdrawal reflexes, neurons' interaction with immunocytes controls host defenses ([@B11]; [@B119]; [@B78]; [@B128]).

Clinically, the denervation of an arthritic joint reversed inflammation in that joint, supporting a role for nociceptor regulation of inflammatory processes ([@B34]). The somatosensory neurons are ideally positioned in lymphoid tissues and in the mucosal barrier to control immune responses ([@B123]). Such microenvironment allows nociceptors to interact with tissue-resident immune cells via the local release of neuropeptides ([@B41]; [@B114]; [@B49]; [@B89]; [@B136]). The peptides generated and locally secreted during neurogenic inflammation promote lymphocyte polarization, controlling the extent and type (1, 2, or 3) of inflammation experienced ([@B52]; [@B53]; [@B37]; [@B99]; [@B123]) as well as stimulating antigen trafficking in the lymph node (LN) ([@B134]; [@B29]; [@B113]; [@B128]).

The effects of sensory neurons on immunity seem to vary between inflammatory context (T~H~1/T~H~17 vs T~H~2), the neuron subpopulation implicated, as well as the nature of the peptides being secreted ([@B49]; [@B8], [@B7]; [@B128]). Typically, substance P (SP) promotes T cell activity and increased dendritic cell (DC) recruitment and recognition of non-self-antigens ([@B23]; [@B116]). Calcitonin gene-related peptide (CGRP) have the inverse action, stopping T cell proliferation and reducing DC migration to LN ([@B92]).

During allergic airway inflammation, IL-5, a type II effector cytokine secreted from several immunocytes, directly activates airway nociceptors, and this leads to the release of VIP. In turn, VIP stimulates ILC2 ([@B99]; [@B123]) and CD4^+^ cells to induce cytokine production, including IL-5, which initiates a positive feedforward pro-inflammatory cycle ([@B123], [@B128]; [@B48]). Neuromedin U (NMU) also stimulates ILC2s, and when given alongside IL-25, it enhances asthma severity ([@B24]; [@B74]; [@B140]). Blocking the NMU--NMUR1 axis decreased ILC2 activity and allergic inflammation ([@B140]). Besides, while CGRP supports ILC2 production of IL-5 ([@B139]), it inhibits alarmin-driven type 2 cytokine production, constrains IL-13 expression, and blocks ILC2 proliferation ([@B95]; [@B139]; [@B153]).

Within the WAT microenvironment, locally released neuropeptides (CGRP, SP) increase immune influx and polarization, heightening WAT inflammation and nociceptor sensitivity ([@B47]). From the data obtained in mouse models of allergic inflammation, one would imagine that CGRP produced by fat pad-innervating sensory neurons would block the function of ILC2s cells, unbalancing the type 1/type 2 immunocyte ratio within the WAT. By favoring T~H~1-mediated immunity, sensory neurons would enhance the influx of pro-inflammatory immune cells such as IL-1β and TNFα-secreting M1 macrophages and IFN-γ-producing ILC1. On the one hand, these cytokines would sensitize nociceptor neurons TRP and Na~V~ channels, triggering pain hypersensitivity; on the other hand, the neurons would locally release more neuropeptides to further imbalance the fat pad local immunity (hypothesized integrated system in [Figure 1](#F1){ref-type="fig"}). Blocking the neuro-immune interplay in such a context would have a twofold, yet synergistic, effect: (i) directly decreased obesity-induced pain trigger by inflammatory cytokines, and (ii) decreased chronic low-grade inflammation. We devised two translational approaches to do this.

![Neuro-immune crosstalk controls obesity-induced pain. Lean individual's adipose tissue is sparsely innervated and comprises few adipocytes and anti-inflammatory immunocytes. The accumulation of fat leads to the rupture of adipocytes and the secretion of adipokines. These mediators increase the chemotaxis of immune cells, enhancing the level of pro-inflammatory cytokines. By acting on their cognate receptors present on sensory nerves, these cytokines sensitize nociceptor neurons by increasing the expression and phosphorylation of NaV and TRP channels. Upon sensitization, the sensory neurons secrete neuropeptides, further polarizing the fat pad's immune cells. QX-314 silences nociceptor neuron's electrical activity, while CNCB2 prevents their release of neuropeptides. By stopping neuro-immune crosstalk, these treatments would help resolve fat pad inflammation and blunt pain hypersensitivity.](fnhum-14-00181-g001){#F1}

Targeting Neuro-Immune Crosstalk {#S10}
================================

First, we modified an efficient pain and itch neuron-blocking strategy to locally silence tumor-innervating nociceptors ([@B113]). This strategy uses large pore TRP channels as a specific drug delivery device to transport charged local anesthetic (such as QX-314) into nociceptor neurons to stop Na^+^ currents. In the context of inflammation, as found in the fat pad micro-environment, TRP channels open, allowing QX-314 (263 Da) to enter these neurons, producing a specific and durable electrical silencing ([@B18]). Of note, QX-314 did not impact immune cell function ([@B123]), confirming its selectivity for inflammation-activated nociceptors ([@B123], [@B127]; [@B48]). This strategy offers three major potential advantages: (1) high specificity (the effect is limited only to sensory neurons that express activated large pore channels), (2) long-lasting activity, and (3) limited side effects; the charge on QX-314 would limit diffusion through lipid membranes and redistribution outside of the respiratory epithelium.

Second, Bean and colleagues devised novel charged N-type Ca^2+^ channel blockers, including an NCE termed CNCB2. The latter induced a prolonged pain blockade and was more potent than its neutral analog at inhibiting nociceptor release of CGRP and acted at lower concentrations to stop the neurogenic inflammation component of asthma. Such cationic molecules are therefore suited to treat pain by stopping potential action generation in nociceptive neurons and reducing inflammation by blocking pro-inflammatory neuropeptide release ([@B81]).

Concluding Remarks {#S11}
==================

Peripheral sensitization is a major contributor to inflammatory pain ([@B1]; [@B150]; [@B65]). Because several sensitizing mediators are released simultaneously during inflammation, stopping one of these mediators is likely to have a limited impact. Silencing sensitized neurons or shared downstream signaling pathways should therefore have larger and provide more prolonged pain relief. Among the others, QX-314, CNCB2, or activation of parasympathetic neurons using bioelectronic medicine, may constitute such broadly acting strategy in reversing the neuro-immune component of obesity-induced inflammation and pain.
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